A meeting of the Committee on Entrepreneurship in Healthcare and Medical Industry of the Ural Chamber of Commerce and Industry was held in Ekaterinburg on March 18, 2025, chaired by Alexander Petrov. Participants of the event, including representatives of the Association of Medical Specialists for Risk Modification, the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region, the Ural Biomedical Cluster and members of the Committee considered key challenges in maintaining the health of the able-bodied population, fighting against socially significant diseases and regulating prices for vital drugs.
The Russian pharmaceutical industry has gained significant stability in the recent years thanks to manufacturers such as Medsintez Plant. This is a modern full-cycle biotechnological enterprise that develops and manufactures pharmaceutical ingredients and drugs that meet international GMP and ISO standards.
On September 26, 2024, TASS hosted an expert discussion in the format of a federal teleconference Moscow-St. Petersburg-Ekaterinburg-Novosibirsk-Vologda-Anapa, dedicated to discussing the role, reasons and mechanisms for stimulating In Ekaterinburg, Alexander Petrov, the Chairman of the Board of Directors of Medsintez Plant LLC, told the participants about Triazavirin, an innovative domestic antiviral drug, as a success case of private investment in science.
60 leading Russian reproductologists visited the pharmaceutical company Medsintez Plant in Novouralsk on September 4, 2024. This event was timed to coincide with the celebration of the 3rd anniversary of the opening of the production workshop for biotechnological substances for the reproductive health of women, as well as the Annual International Conference «Reproductive Technologies Today and Tomorrow» in Ekaterinburg. Leading experts and conference speakers visited the production of the first Russian follitropin alpha for the treatment of human infertility, Primapur®.
Nonprofit Partnership "Ural Biomedical Cluster" was founded in December 2010 as a comprehensive innovative project. Its difference from an industrial cluster is that, in addition to manufacturing facilities, there are research centers, laboratories for preclinical studies, educational structures and clinics successfully operating based on the Cluster.
Strategic goal of the Ural Biomedical Cluster is to form a high-tech complex of interconnected production and infrastructure facilities for development, production and sale of modern medicines, medical equipment and high- quality medical devices in the Urals region.
The global mission of the Ural Biomedical Cluster is a widespread increase in availability of advanced medical technologies in Russia.
Today, the Ural Biomedical Cluster includes over 30 companies.
Ural Biomedical Cluster Services:
Intellectual Property
Management Patent search, detection of patented technologies, patent landscape designing, intellectual property protection, legal support.
Project Management
Development and execution of a registration dossier, support, business planning, investor search, strategic planning.
Technology Transfer
Development and scaling of original formulations for pharmaceutical products and drugs, existing technologies transfer to a specific site (localization of production).
Human Resources
Personnel training upon request: master's degree, residency, advanced training courses, internships at the enterprises of the Cluster and partners.
Contract Manufacturing
Manufacturing of pharmaceutical products and medical devices to order.
Related Services
Provision of office, laboratory and production premises, logistics services.
Articles of Association dated 24/9/2012